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Abstract
Background: We recently demonstrated the cytotoxicity of liquid crystal precursors (hereafter referred to as
“mesogenic compounds”) in the human non-small cell lung cancer (NSCLC) cell line A549 which carry wild-type
p53. p53 mutations are observed in 50 % of NSCLC and contribute to their resistance to chemotherapy. To develop
more effective and cancer-specific agents, in this study, we investigated the structure–activity relationships of
mesogenic compounds with cytotoxic effects against multiple NSCLC cells.
Methods: The pharmacological effects of mesogenic compounds were examined in human NSCLC cells (A549,
LU99, EBC-1, and H1299) and normal WI-38 human fibroblast. Analyses of the cell cycle, cell-death induction, and
capsases expression were performed.
Results: The 3-ring compounds possessing terminal alkyl and hydroxyl groups (compounds C1–C5) showed
cytotoxicity in NSCLC cells regardless of the p53 status. The compounds C1 and C3, which possess a pyrimidine at
the center of the core, induced G2/M arrest, while the compounds without a pyrimidine (C2, C4, and C5) caused G1
arrest; all compounds produced caspase-mediated cell death. These events occurred in a p53-independent manner.
Furthermore, it was suggested that compounds induced cell death through p53-independent DNA damage-
signaling pathway. Compounds C2, C4, and C5 did not show strong cytotoxicity in WI-38 cells, whereas C1 and C3
did. However, the cytotoxicity of compound C1 against WI-38 cells was improved by modulating the terminal alkyl
chain lengths of the compound.
Conclusions: We showed the p53-indepdent structure–activity relationships of mesogenic compounds related to
the cytotoxic effects. These structure–activity relationships will be helpful in the development of more effective and
cancer-specific agents.
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Background
Lung cancer is the leading cause of cancer-related death
over the world among both men and women. Non-small
cell lung cancer (NSCLC) accounts for 85 % of all cases
of lung cancer, and the overall 5-year survival rate of pa-
tients with NSCLC remains lower than 15 % [1]. To im-
prove the survival of patients with NSCLC, anticancer
agents such as molecular-targeted drugs [2–4] are under
development. However, few drug therapies lead to
complete recovery in patients with NSCLC. Therefore,
development of more effective anticancer drugs is essen-
tial for the treatment of NSCLC.
p53 is a tumor suppressor gene that plays critical roles
in cellular responses, such as cell cycle arrest and
apoptosis, after exposure to various stresses including
DNA damage [5]. In response to DNA damage such as
ionizing radiation, ataxia–telangiectasia mutated/ataxia–
telangiectasia and Rad-3-related (ATM/ATR), which is a
DNA damage sensor, stabilizes and activates p53; acti-
vated p53 then transcriptionally regulates apoptosis-
related genes as well as cell cycle arrest-related genes
[6]. In addition to transcriptional activity, p53 can acti-
vate the intrinsic mitochondrial-mediated pathway of
apoptosis in a transcriptional-independent manner by
interacting with B-cell lymphoma file family members
[7]. The importance of p53 in cancer treatment has been
shown in many studies [8–11]. For example, the loss of
p53 function in lung cancers results in resistance to not
only radiation but also molecularly targeted drugs such
as epidermal growth factor receptor inhibitors [10, 11].
This is at least in part due to the impairment of p53-
mediated apoptosis induction [12, 13]. Since p53
mutations are observed in 50 % of NSCLC [14] and con-
tribute to their resistance to chemotherapy [15], drugs
exerting anticancer effects independent of p53 are re-
quired for NSCLC treatment.
Liquid crystals (LCs) are compounds that exist in a
state of matter between liquid and crystalline phases and
can be characterized by the loss of positional order while
maintaining orientational order [16]. Lyotropic LCs can
be found in the LC phase depending on both the
temperature and the concentration of LC molecules in a
solvent; these compounds are observed in biological
structures such as cell membranes, which are comprised
of a lamellar bilayer of mesophases of phospholipids,
glycolipids, and cholesterol. Some studies have focused
on the structural affinities of cell membranes for LCs
and have assessed the application of LCs as drug-
delivery systems [17, 18]. In previous studies, we investi-
gated the cytotoxicity of LC compounds and their pre-
cursors (mesogenic compounds) [19–23] and showed
that some amphiphilic LC compounds, such as cyanobi-
phenyl derivatives with terminal hydroxyl moieties, mod-
erately suppressed cell growth in the NSCLC cell line
A549 [20]. Furthermore, an amphiphilic LC precursor
with three aromatic rings dramatically suppressed cell
growth and induced apoptosis in A549 cells, but it also
showed low cyototoxicity in normal WI-38 fibroblast
cells [22]. To explore and further develop the potential
application of LC precursors as anticancer drugs, we in-
vestigated the structure–activity relationships of various
LC precursors and their analogs and examined their
cytotoxic effects in multiple NSCLC cell lines, both with
and without p53. Here we demonstrated that not only
the 3-ring structure with terminal alkyl and hydroxyl
groups but also the alkyl chain lengths are structurally
important for the cytotoxic effects of mesogenic com-
pounds against human NSCLC cells. Furthermore, we
showed the p53-indepdent structure–activity relation-




Test compounds (Fig. 1a) were dissolved in dimethyl
sulfoxide (DMSO; Sigma–Aldrich, St Louis, MO, USA)
at 10 mM concentration. 2-(4-Hexyloxyphenyl)-5-(4-
hydroxyphenyl)pyrimidine (C1) and its homologous
series (as shown in Fig. 1f ), 2-(4-hexylphenyl)-5-(4-
hydroxyphenyl)pyrimidine (C3), 2-(4-hydroxyphenyl)-5-
hexylpyrimidine (C6), and 2,5-bis(4-hexyloxyphenyl)
pyrimidine (C7) were purchased from Midori Kagaku
Co., Ltd. (Tokyo, Japan). 2-[4-(Hexyloxy)phenyl]-5-(4-
hydroxyphenyl)pyridine (C2), 2-[4-(4-hydroxyphenyl)
phenyl]-5-hexylpyrimidine (C4), and 2-[4-(4-hydroxyphenyl)
phenyl]-5-hexylpyridine (C5) were provided from Japan En-
ergy Corporation (Tokyo, Japan).
The octanol-water coefficient (logP) values were calcu-
lated using ChemDraw software (Perkin Elmer Informatics).
Reagents
Propidium iodide (PI) and caffeine were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Z-Val-Ala-Asp
(OMe)-CH2F (Z-VAD-fmk) was purchased from Peptide
Institute, Inc. (Osaka, Japan). The fluorescein isothiocyan-
ate (FITC)-labeled monoclonal antibody anti-human clus-
ter of differentiation 95 (CD95-FITC) was purchased from
BioLegend (San Diego, CA, USA). FITC-conjugated anti-
mouse IgG1 antibody was purchased from Beckman–
Coulter (Fullerton, CA, USA). Kp7-6 was purchased from
EMD Millipore (Darmstadt, Germany). β-actin antibody
(#4967), p53 antibody (#9282), cyclin B1 antibody (#4135),
phospho-cdc2 (Tyr15) antibody (#9111), phospho-Histone
H3 (Ser10) antibody (#3377), caspase-3 antibody (#9662),
caspase-8 antibody (#9746), caspase-9 antibody (#9502),
phosphor-ATM (Ser1981) (D25E5) antibody (#13050),
anti-rabbit IgG horse radish peroxidase (HRP)-linked anti-
body (#7074), and anti-mouse IgG HRP-linked antibody
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(#7076), Alexa Fluor® 488-conjugated goat anti-rabbit IgG
(#4412) were purchased from Cell Signaling Technology
Japan, K.K. (Tokyo, Japan). Goat anti-actin polyclonal
antibody (sc-1615), rabbit anti-p21 polyclonal antibody
(sc-756), and HRP-conjugated donkey anti-goat IgG anti-
body (sc-2056) were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). For knockdown of
p53, Ambion’s Silencer® select pre-designed siRNA (ID:
s606) and Silencer® select negative control 1 were pur-
chased from Life Technologies Corporation (Carlsbad,
CA, USA).
Cell culture and treatment
A549 (p53 wild type) human lung cancer cells and WI-
38 normal human fibroblasts (embryonic fibroblast,
lung-derived cell line) were purchased from the Riken
Bio-Resource Center (Tsukuba, Japan). LU99 (p53 wild
type) and EBC-1 (p53 mutant) human lung carcinoma
cells were purchased from the JCRB Cell Bank (Osaka,
Japan). H1299 (p53-null) human lung carcinoma cells
were purchased from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA). The A549 cells
were maintained in Dulbecco’s modified Eagle’s medium
(Sigma–Aldrich) supplemented with 1 % penicillin/
streptomycin (GIBCO®; Invitrogen, CA, USA) and 10 %
heat-inactivated fetal bovine serum (FBS; Japan Bioserum
Co., Ltd., Japan) at 37 °C in a humidified atmosphere con-
taining 5 % CO2. WI-38 and EBC-1 cells were cultured in
Eagle’s minimum essential medium (Sigma–Aldrich) sup-
plemented with 1 % penicillin/streptomycin and 10 %
heat-inactivated FBS at 37 °C in a humidified atmosphere
containing 5 % CO2. The LU99 and H1299 cells were
maintained in RPMI1640 (GIBCO®) supplemented with
1 % penicillin/streptomycin and 10 % heat-inactivated FBS
at 37 °C in a humidified atmosphere containing 5 % CO2.
NSCLC cell lines (6.0 × 104 cells) or WI-38 cells (6.0 ×
104 cells) were seeded onto 35-mm culture dishes (Iwaki,
Chiba, Japan) and were cultured overnight to allow ad-
herence to the dish. On the next day, compounds were
added to the culture medium (at a final concentration of
10 μM) and cells were cultured for 3 days. For cell cycle
analysis, NSCLC cell lines (1.2 × 105 cells) were seeded
onto 60-mm culture dishes (Iwaki, Chiba, Japan). Cells
were subsequently harvested using 0.1 % trypsin-
ethylenediaminetetraacetic acid (Gibco®; Invitrogen), and
viable cells were counted using the trypan blue dye ex-
clusion method. Because LU99 cells were loosely ad-
hered to the dish, they were harvested without the use
of trypsin-ethylenediaminetetraacetic acid. Cell survival
was expressed as the rate of viable cell number against
a b d e
c f g
Fig. 1 Effects of test compounds on the growth of non-small cell lung cancer (NSCLC) cells. a The structures of the test compounds are shown. b, d–e
NSCLC cells cultured in the presence of compounds C1–C7 at 10 μM for 3 days were harvested, and viable cells were counted using trypan blue exclusion
assays. Dotted lines indicate the dimethyl sulfoxide control. Data are presented as the mean ± SE of 3 independent experiments. c A549 cells cultured in
the presence of compounds C1–C2 at 10 μM for 1–3 days were harvested, and viable cells were counted using trypan blue exclusion assays. Results are
shown as relative value against input cell number. Data are presented as the mean ± SE of 3 independent experiments. f Structural formulae of C1 and its
derivatives with differing alkyl chain lengths and cytotoxic effects against A549 cells [left panel] and the other NSCLC cells [light panel]; data are presented
as mean ± SE of 3 independent experiments. g The logP values of test compounds are shown
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the vehicle (DMSO)-treated cells. No significant cytotox-
icty of DMSO treatment was observed in any of the cell
lines.
siRNA transfection
A549 cells were transfected with p53-targeting siRNA
(p53 siRNA) or control siRNA using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacture’s
recommended protocol. The final concentration of
siRNA was 5 nM. After 24 h incubation, the transfected
cells were harvested and used for subsequent analyses.
Cell cycle analysis
The cells treated with compounds were harvested and
fixed in 70 % ethanol overnight at −20 °C. The fixed cells
were washed with Ca(2+)- and Mg(2+)- free phosphate-
buffered saline [PBS(−)] and then treated with RNase A
(200 μg/mL) at 37 °C for 30 min to hydrolyze RNA.
After treatment, the cells were washed with PBS(−) and
stained with PI (30 μg/mL) for 30 min in the dark. Then,
the cells were filtered with cell strainer (BD Falcon™,
Franklin Lakes, NJ, USA). The cell-cycle distribution was
analyzed by flow cytometry (Cytomics FC500, Beckman–
Coulter).
SDS-PAGE and western blotting
SDS-PAGE and western blotting were performed as previ-
ously described [24]. The following primary antibodies
were used: rabbit anti-p53 antibody (1:4000), rabbit anti-
p21 polyclonal antibody (1:4000), rabbit anti-phospho-
Histone H3 antibody (1:3000), rabbit anti-phospho-cdc2
antibody (1:3000), mouse anti-cyclin B1 antibody (1:3000),
rabbit anti-caspase-3 antibody (1:3000), mouse anti-
caspase-8 antibody (1:3000), rabbit anti-caspase-9 anti-
body (1:3000), rabbit anti-β-actin antibody (1:5000), or
goat anti-actin polyclonal antibody (1:5000). Each primary
antibody was diluted in Can Get Signal® Immunoreaction
Enhancer Solution 1 (TOYOBO, Co., Ltd, Osaka, Japan).
The following secondary were used: HRP-linked anti-
rabbit IgG antibody (1:10000), HRP-linked anti-mouse
IgG antibody (1:10000), or HRP-conjugated donkey anti-
goat IgG antibody (1:10000). Each secondary antibody was
diluted in Can Get Signal® Immunoreaction Enhancer
Solution 2 (TOYOBO). The antigens were visualized by
the ECL Prime Western Blotting Detection System (GE
Healthcare). Blot stripping was performed using Stripping
Solution (Wako Pure Chemical Industries).
In vitro irradiation
Radiation exposures (150 kVp, 20 mA, 0.5-mm Al and
0.3-mm Cu filters) were performed using an X-ray gen-
erator (MBR-1520R-3, Hitachi Medical Corporation,
Tokyo, Japan) at a distance of 45 cm from the focus at a
dose rate of 1.04 Gy/min.
Analysis of apoptosis
Cell death was analyzed by annexin V-FITC (BioLegend)
and PI staining according to the manufacturer’s instruc-
tions. In brief, the cells treated with each compound were
harvested, washed, and suspended in annexin V Binding
Buffer (BioLegend). The annexin V-FITC (2.5 μg/mL) and
PI solution (50 μg/mL) were added to the cell suspension
and incubated for 15 min at room temperature in the
dark. Then, the apoptotic cells were analyzed by flow cy-
tometry (Cytomics FC500, Beckman–Coulter). In the
annexin V/PI quadrant gating, annexin V(−)/PI(−),
annexin V(+)/PI(−), and annexin V(+)/PI(+) were used
to identify the fraction of viable cells, early apoptotic
cells, and late apoptotic/necrotic cells, respectively.
Detection of active caspase-3
An FITC-conjugated monoclonal active caspase-3 anti-
body apoptosis kit (BD Biosciences, San Diego, CA,
USA) was used to detect active caspase-3 according to
the manufacturer’s instructions. In brief, the cells treated
with each compound were harvested, washed, and sus-
pended in Cytofix/Cytoperm™ buffer. The cell suspen-
sions were placed on ice for 20 min and washed with
Perm/Wash™. Then, the cells were resuspended in
Perm/Wash™ buffer containing 10 % FITC-conjugated
caspase-3 antibody and incubated for 30 min at room
temperature in the dark. The cells were washed and ana-
lyzed by flow cytometry.
Treatment with various inhibitors
Cells were preincubated with each inhibitor, 50 μM Z-
VAD-fmk (a pan-caspase inhibitor), 1 mM kp7-6 (Fas/
Fas ligand antagonist), or 2 mM caffeine (an inhibitor of
ATM/ATR) for 1 h, and then test compounds were
added to the respective cultures. After culture in the
presence of the compounds for 24–72 h, the cells were
harvested and viable cells were counted. Subsequently,
analyses of cell cycle, cell death (annexin V-FITC and PI
staining), or caspase-3 expression were performed as de-
scribed above.
Analysis of cell surface CD95 (Fas) expression
Cells treated with compounds were harvested and then
washed in PBS(−). Cells were then stained with FITC-
conjugated CD95 antibody for 30 min at 4 °C in the
dark. After staining, cells were washed and analyzed
using flow cytometry. Before analysis, 25 μg/ml PI was
added to cell suspensions to discriminate dead cells from
viable cells. After gating PI negative cells, the fluores-
cence intensity of CD95 staining was analyzed.
Intracellular phosphorylated-ATM staining
Intracellular phosphorylated-ATM (Ser1981) expression
was analyzed using a flow cytometer. Cells treated with
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compounds were harvested and then washed with
PBS(−). The cells were fixed in 4 % formaldehyde
(Sigma–Aldrich) for 10 min at 37 °C. After washing with
PBS(−), the cells were permeabilized with 90 % methanol
overnight at −20 °C. After washing with incubation buf-
fer (PBS containing 0.5 % bovine serum albumin), cells
were suspended in incubation buffer containing primary
phosphorylated-ATM antibody (1:1600) for 1 h at room
temperature. After washing with incubation buffer, cells
were stained with Alexa Fluor® 488-conjugated anti-
rabbit secondary antibody (1:1000) at room temperature
in the dark. As a control, cells were stained with Alexa
Fluor® 488-conjugated secondary antibody alone. After
30 min, cells were washed with incubation buffer and
were analyzed using flow cytometry.
Statistical analysis
Data are presented as mean ± SE. Comparisons between
control and experimental groups were made using two-
sided Mann–Whitney’s U-test or two-sided Student’s t-
test depending on the normality of data distributions.
Differences were considered significant when p < 0.05.
Excel 2010 software (Microsoft, USA) with the add-in
software Statcel 3 [25] was used to perform these statis-
tical analyses.
Results
Cytotoxic effects of compounds
We have previously showed that 2-(4-butoxyphenyl)-5-
(4-hydroxyphenyl) pyrimidine (the compound with 4-
carbon alkyl chains in Fig. 1f ), which is a LC-related
compound, dramatically suppresses the growth of A549
cells [22]. Based on this, we developed the mesogenic
compounds C1 and C2 (Fig. 1a). Although the structural
difference between C1 and C2 is the presence of a pyr-
imidine at the center of the core, both of these com-
pounds showed cytotoxicity to all the tested NSCLC cell
lines (Fig. 1b). Of note, these cytotoxic effects were inde-
pendent of p53 status. When the dose–response effects
of C1 and C2 were examined in A549 cells (Additional
file 1: Figure S1), we found that the 50 % inhibitory con-
centrations (IC50) of these compounds were 1.9 ±
0.1 μM for C1 and 2.3 ± 0.2 μM for C2; the cytotoxic ef-
fects of these compounds saturated around 10 μM.
Therefore, a concentration of 10 μM was used in subse-
quent experiments. Furthermore, treatment with C1 and
C2 at 10 μM finally gave similar cytotoxicity, although
the time dependence of these effects differed between
C1 and C2 (Fig. 1c). In brief, C1 showed a dramatic
cytotoxicity already at 1 day, while the strong cytotox-
icity of C2 was observed at 3 day.
To clarify the structure–activity relationship of meso-
genic compounds, we first focused on the core structure
(Fig. 1d). The presence of an ether linkage between the
terminal alkoxyl and the core did not affect cytotoxicity.
Compounds C4 and C5, which possess a nitrogen-
containing p-terphenyl link, retained cytotoxicity,
although we found that the cytotoxic effects varied de-
pending on the presence and position of the pyrimidine.
However, 2-ring compounds failed to show cytotoxicity.
These results suggested that p-terphenyl is important for
cytotoxic effects.
Next, we investigated structure–activity relationships
in terms of the terminal alkoxyl and hydroxyl groups
(Fig. 1e). Compounds with alkoxyl groups at both ends
did not show cytotoxicity despite possessing a p-terphe-
nyl. We then investigated whether alkyl chain length
modulates cytotoxicity (Fig. 1f ). Compound C1, with 6-
carbon alkyl chains, had the highest cytotoxicity.
Compounds with <6-carbon alkyl chains (n = 4 or 5) also
dramatically suppressed cell growth, but cytotoxic effects
decreased when the alkyl chain length exceeded 6 car-
bons (n = 8 and 10). These findings show that the pres-
ence of p-terphenyl with terminal alkoxyl and hydroxyl
groups is structurally important for cytotoxicity.
As the lipophilicity of each compound contributes to
properties such as solubility and permeability through
biological membranes [26], we compared each com-
pound’s logP as an estimate of a compound’s overall
lipophilicity. As shown in Fig. 1g, the cytotoxic com-
pounds C1–C5 had similar logP values (5.68–6.38).
Mesogenic compounds affect cell cycle distribution
Since anticancer drugs suppress tumor cell growth in
part through modulation of the cell cycle, we next inves-
tigated the effects of the cytotoxic compounds C1–C5
on the cell cycle distribution of NSCLC cells. As shown
in Fig. 2a, the cell cycle kinetics of NSCLC cells treated
with C1 were dramatically different from those treated
with C2. Compounds C1 and C3, which have a pyrimi-
dine at the center of the core, induced G2/M arrest
(Fig. 2a-b and Additional file 2: Figure S2). In the case of
C1, G2/M arrest was induced at 6 and 12 h in LU99
cells (data not shown), although it was not maintained at
24 h in this cell line. In contrast, the compounds without
a pyrimidine at the center of the core (compounds C2,
C4, and C5) induced G1 cell cycle arrest in A549 and
H1299 cells (Fig. 2b). These results indicate that meso-
genic compounds carrying p-terphenyl with terminal
alkoxyl and hydroxyl groups affect cell cycle distribution,
and that compounds possessing a pyrimidine at the cen-
ter of the core induce G2/M arrest regardless of p53 sta-
tus in NSCLC cells.
Next, to investigate the role of p53 in the G2/M arrest
caused by C1 in p53-wild-type A549 cells, we examined
the expression levels of p21, which is a transcriptional
target of p53 and participates in the G2 checkpoint [27].
Although high levels of p21 expression were observed in
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irradiated A549 cells, treatment with C1 did not change
the expression of p21, despite both treatments leading to
G2/M arrest (Fig. 3a). In addition, treatment with caf-
feine, an ATM/ATR inhibitor [28], hardly affected the
C1-induced G2/M arrest, whereas it abrogated the
irradiation-induced G2/M arrest (Fig. 3b). These results
indicate that ATM/ATR-p53-p21 axis is not involved in
the C1-induced G2/M arrest. Furthermore, we analyzed
the cell cycle distribution of A549 cells transfected with
p53-targeting siRNA. Although knockdown of p53 di-
minished the C1-induced p53 expression (Fig. 3b), the
increase of G2/M fraction after C1 treatment was ob-
served in p53-siRNA trasfected A549 cells (Fig. 3c).
These results strongly indicate that C1 induces G2/M ar-
rest in A549 cells in a p53-independent manner.
Cdc2/cyclin B1 kinase plays a key role in regulating the
G2/M transition [29–31]. The expression of cyclin B1
began to increase during G2 and peaks in mitosis. On the
other hand, dephosphorylation of cdc2 activates the
cdc2/cyclin B1 kinase and triggers the cell to enter into
mitosis. Since it is reported that a natural plant product
curcumin can induce a similar G2/M arrest in human
colorectal cancer lines HCT-116 (p53+/+), HCT-116 (p53
−/−), and HCT-116 (p21−/−) by regulating cdc2/cyclin B1
kinase activity [32], we investigated the expression of cyc-
lin B1 and phosphorylated-cdc2 (Tyr15) in A549 cells
treated with C1. As shown in Fig. 3e, the expression of
cyclin B1 was increased after C1 treatment for 12 h, while
C1 decreased the phosphorylation of cdc2. These results
suggest that cdc2/cyclin B1 kinase is activated after C1
treatment and that C1 treatment induces mitotic arrest ra-
ther than G2 arrest. In line with these results, the expres-
sion of phosphorylated-histone H3 (Ser10), a marker of
mitotic cells, was observed in A549 cells treated with C1
(Fig. 3e). Furthermore, the analysis of nuclear morphology
showed the increase of mitotic cells by C1 treatment
(Additional file 3: Figure S3). Taken together, these results
indicate that C1 induces mitotic arrest.
a
b
Fig. 2 Effects of test compounds on cell cycle progression. a Non-small cell lung cancer (NSCLC) cells cultured in the presence of test compounds
(C1–C2) at 10 μM for 24–48 h were harvested, and then cell cycle profiles were analyzed. Representative histograms of three different experiments
are shown. b NSCLC cells cultured in the presence of test compounds (C1–C5) at 10 μM for 24–48 h were harvested, and then cell cycle profiles
were analyzed. Fractions of G2/M at 24 h in NSCLC cells (A549, LU99, EBC-1, and H1299 cells) [left panel] and G1 at 48 h in A549 and H1299 cells
[light panel] are shown. Data are presented as mean ± SE of 3 independent experiments. * and ** indicate p < 0.05 and p < 0.01 compared with
dimethyl sulfoxide control, respectively
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Mesogenic compounds cause apoptosis
To further verify the cytotoxic effects of our mesogenic
compounds, we estimated apoptosis by sub-G1 fraction
or annexin V-FITC and PI staining. As shown in Fig. 4a,
treatment with C1–C5 increased the sub-G1 fraction,
which is one of the hallmarks of apoptosis, in all NSCLC
cell lines. Furthermore, C1–C5 induced annexin V(+)/
PI(−) and/or V(+)/PI(+) dead cells (Fig. 4b). These
results indicate that mesogenic compounds carrying p-
terphenyl with terminal alkoxyl and hydroxyl groups in-
duce cell death, including apoptotic death, in NSCLC
cells regardless of p53 status.
Involvement of caspase in mesogenic compound-induced
cell death
Because caspase-3 is a key effector protease responsible
for DNA fragmentation during apoptosis, caspase-3 acti-
vation was examined. The expression of active caspase-3
was approximately 20 % higher in A549 cells treated
with C1 for 48 h or C2 for 72 h than in the control cells,
and this expression was reduced in the presence of the
pan-caspase inhibitor Z-VAD-fmk (Fig. 5a). In line with
the reduction of active caspase-3 expression, treatment
with Z-VAD-fmk decreased C1- and C2-induced sub-G1
fractions in A549 cells (Fig. 5b). Furthermore, C1- and
C2-induced active caspase-3 expression and sub-G1
fractions in p53-null H1299 cells were decreased by Z-
VAD-fmk (Fig. 5c and d). Similar results were observed
for C3–C5 treatment (data not shown). These results in-
dicate that mesogenic compounds induce caspase-
mediated cell death independent of p53.
Mesogenic compounds induce Fas-mediated cell death
Since the executioner caspase-3 can be activated by an
extrinsic (capase-8) and/or an intrinsic pathway
(capsase-9), we analyzed the expression of caspase-8 and
-9 in A549 cells treated with C1 and C2. As shown in
Fig. 6a, C1 and C2 induced both cleaved caspase-8 and
cleaved caspase-9 expression. We next investigated the
involvement of Fas in cell death induced by our com-
pounds because Fas induces caspase-mediated cell death




Fig. 3 Involvement of p53 in compound C1–induced G2/M arrest. a A549 cells were treated with C1 for 12 h and harvested for western blotting
of p53 and p21 and cell cycle analyses. As a positive control, A549 cells were irradiated with 10 Gy X-ray and harvested 12 h after irradiation for
Western blotting analyses of p53 and p21; actin was used as a loading control. Representative blots of two different experiments are shown
[upper panel]. Representative histograms of two different experiments are shown [lower panel]. b A549 cells preincubated with the caffeine were
cultured in the presence of 10 μM C1 for 24 h [left panel] or cultured for 12 h after 10 Gy-irradiation [right panel]. The cells were harvested, and
cell cycle analysis was performed. Representative histograms of two different experiments are shown. c–d A549 cells treated with p53 siRNA were
cultured in the presence of C1 at 10 μM for 12 h, and then western blotting of p53 (c) and cell cycle profiles (d) were analyzed. Representative
results of two different experiments are shown. e A549 cells were treated with C1 for 12–24 h and harvested for western blotting of phospho-
cdc2 (p-cdc2), cyclin B1, and phospho-histone H3 (p-H3). Representative results of two different experiments are shown
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treated with C1 for 48 h was approximately 2-fold higher
than that in control cells. Furthermore, C1-induced cell
death was significantly prevented by treatment with the
Fas/Fas ligand antagonist kp7-6 [34] (Fig. 6c), indicating
that C1 induces Fas-mediated cell death. Similarly, treat-
ment with C2 increased Fas expression and C2-induced
cell death was also decreased by kp7-6 (Fig. 6b and c).
These results suggest that 3-ring compounds carrying
terminal alkoxyl and hydroxyl groups may possess struc-
turally important features for Fas-mediated cell death
that are independent of the central pyrimidine moiety.
Involvement of DNA damage-signaling pathway in
mesogenic compound-induced cell death
Since a number of chemotherapeutic drugs cause cyto-
toxicity through DNA damage [35], we investigate
whether mesogenic compounds induce cell death
through DNA damage. The serine/threonine protein
kinase ATM plays key role in DNA damage response
such as DNA repair, cell cycle arrest, and apoptosis [6].
Following DNA damage, ATM activates itself by auto-
phosphorylation at Ser1981 [36]. Once activated, ATM
phosphorylates numerous substrates involving in DNA
damage response such as p53 and checkpoint kinases
[6]. As shown in Fig. 7a, the phosphorylation of ATM at
Ser1981 was increased in A549 cells treated with C1 and
C2 as well as irradiation. Furthermore, treatment with
caffeine significantly decreased the compounds-induced
cell death (Fig. 7b). These results suggest that mesogenic
compounds induce cell death through DNA damage-
signaling pathway.
We next investigated whether p53 involves in the
compounds-induced cell death in A549 cells. Although
knockdown of p53 decreased the C1- and C2-induced
p53 protein expression in A549 cells (Fig. 7c), it did not
decreased those compounds-induced cleaved caspases-3
expression and cell death (Fig. 7c and d), thus suggesting
that mesogenic compounds induce cell death through
a b
Fig. 4 Effects of test compounds on cell death induction. a Non-small cell lung cancer (NSCLC) cells cultured in the presence of test compounds
(C1–C5) at 10 μM for 72 h were harvested, and then cell cycle profiles were analyzed. Sub-G1 fractions in cells are presented as mean ± SE of 3
independent experiments. b NSCLC cells were cultured in the presence of test compounds (C1–C5) at 10 μM for 72 h (A549, LU99, and H1299
cells) or for 96 h (EBC-1 cells). Cells were harvested, and then annexin V/propidium iodide (PI) staining was performed. Representative histograms
of three different experiments are shown, and the inset numbers are the percentage of annexin(+)/PI(−) and annexin(+)/PI(+) cells
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DNA damage-signaling pathway, but it is independent
of p53.
Cytotoxic effects of compounds in normal human
fibroblast WI-38 cells
In further experiments, we investigated whether our
mesogenic compounds suppress the growth of WI-38
normal human fibroblast cells. As shown in Fig. 8a, C1
and C3, which carry a pyrimidine at the center of the
core, dramatically suppressed WI-38 cell. In contrast, no
cell growth suppression of WI-38 cells was observed
with compounds C2, C4, and C5. The cell cycle analyses
showed that compounds C1 and C3 induced G2/M ar-
rest in WI-38 cells as well as NSCLC cells (Fig. 8b).
We next examined whether the alkyl chain length
modulates cytotoxicity against WI-38 cells. Compound
C1, which has a 6-carbon alkyl chain, caused the largest
effect (Fig. 8c). Although compounds with 4- or 5-
carbon alkyl chains dramatically suppressed the growth
of NSCLC cells (Fig. 1f ), those compounds showed only
moderate cytotoxicity against WI-38 cells (approxi-
mately 40 % inhibition; Fig. 8c).
Discussion
In this study, we investigated the cytotoxic effects of meso-
genic compounds on human NSCLC cells and showed
their corresponding structure–activity relationships. First,
we demonstrated that 3-ring compounds carrying terminal
alkyl and hydroxyl groups had superior cytotoxic effects
against NSCLC cells, regardless of p53 status. Furthermore,
we showed that these compounds affect cell cycle regula-
tion lead to induction of apoptosis. In brief, compounds C1
and C3, which have a pyrimidine at the center of the core,
induced caspase-mediated cell death following G2/M ar-
rest, while compounds without a pyrimidine at the center
a b
c d
Fig. 5 Involvement of caspase in mesogenic compound-induced cell death. a–b A549 cells were preincubated with Z-VAD-fmk for 1 h and then
cultured in the presence of 10 μM C1 for 48 h or C2 for 72 h. Cells were then harvested, and analyses of active caspase-3 expression and sub-G1
fractions were performed. a Representative histograms of three different experiments are shown, and inset numbers indicate percentages of
active caspase-3-positive cells. Z-VAD indicates Z-VAD-fmk. b Sub-G1 fractions are presented as mean ± SE of 4 independent experiments.
* indicates p < 0.05. c–d H1299 cells were preincubated with Z-VAD-fmk for 1 h and then cultured in the presence of 10 μM C1 or C2 for 72 h.
Cells were then harvested, and analyses of active caspase-3 expression and sub-G1 fractions were performed. c Representative histograms of two
different experiments are shown, and inset numbers indicate percentages of active caspase-3-positive cells. d Sub-G1 fractions are presented as
mean ± SE of 3 independent experiments. * indicates p < 0.05
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of the core (C2, C4, and C5) induced caspase-mediated cell
death following G1 arrest in a p53-independent manner.
LogP is an estimate of a compound’s overall lipophilic-
ity, which contributes to solubility and permeability
through biological membranes; there are some reports
that logP is a determinant factor in the anticancer effects
of some compounds [37, 38]. Supek et al. reported that
the optimum logP of crown ether compounds is ap-
proximately at 5.5 for anticancer effects [38]. In the
present study, logP values of our 3-ring mesogenic com-
pounds showing cytotoxicity (C1–C5 and compounds
with 4- or 5-carbon alkyl chains) ranged from 4.84 to
6.38 in NSCLC cells. Interestingly, the logP value of 3-
ring compounds increased with alkyl chain lengths (the
logP values of compound with 4-, 5-, 6-, 8-, and 10-
carbon alkyl chains are 4.84, 5.26, 5.68, 6.52, and 7.36,
respectively), and compounds with alkyl chain lengths
exceeding six carbons showed lower cytotoxicity. There-
fore, the lower cytotoxity of those compounds might be
explained by their high lipophilicity. In contrast, com-
pound with 4-carbon alkyl chains showed a strong cyto-
toxicty at 10 μM (Fig. 1f ), although its logP value (4.84)
was lower than the other cytotoxic compounds. How-
ever, the IC50 value of this compound in our previous
work was approximately 5.5 μM [22], which was higher
than that of C1 with 6-carbon alkyl chains (1.9 μM).
These results suggest that the relatively low lipophilicity
also results in low cytoxicity.
We demonstrated that C1 can induce mitotic arrest
followed by cell death, thus suggesting that C1 has po-
tential to function as antimitotic agent. Some chemo-
therapeutic agents targeting mitosis are clinically used or
currently developed for cancer treatment [39–41]. For
example, vinca alkaloids (vincrstine, vinblastine, and vin-
desine) or taxanes (paclitaxel and docetaxel) inhibit mi-
tosis by disrupting microtubule dynamics [42]. In
addition, the inhibition of mitotic-specific kinases (e.g.,
polo-like kinase 1 and aurora kinases) involving in spin-
dle formation and mitotic checkpoint results in atimito-
tic effect [43]. Therefore, it is possible that C1 affects the
microtubules or the mitosic-specific kinases, although
we need to investigate it in future analyses.
The present study showed that 3-ring compounds car-
rying terminal alkyl and hydroxyl groups induced
caspase-mediated cell death independent of p53. We
also showed that Fas mediates the cell death induced by
compounds C1 and C2. Ferreira et al. reported that anti-




Fig. 6 Involvement of Fas in compound-induced cell death of A549 cells. a A549 cells were treated with C1 or C2 for 72 h and harvested for
western blotting of caspase-8 and caspase-9. Representative results of two different experiments are shown. b A549 cells cultured in the presence
of 10 μM C1 for 48 h or C2 for 72 h were harvested, and cell surface Fas expression was analyzed. Representative histograms of three different
experiments are shown. The dotted line histogram indicates cells stained with isotype control. The broken line and filled gray histograms indicate
Fas expression in cells treated with vehicle and compound, respectively. Inset numbers indicate mean fluorescence intensities relative to the
vehicle control. c A549 cells were preincubated with the Fas/Fas ligand antagonist kp7-6 and were cultured in the presence of 10 μM C1 for 48 h
[left panel] or C2 for 72 h [right panel]. Cells were harvested and annexin V/propidium iodide staining was performed. Percentages of annexin V(+)
cells are presented as the mean ± SE of 3 independent experiments; * indicates p < 0.05
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and paclitaxel, which are typically used in lung cancer
treatment, induce apoptosis without using the Fas/Fas
ligand signaling pathway [44]. Therefore, it is likely that
there will be synergistic effects between our mesogenic
compounds and these anticancer drugs.
Compounds C1 and C2 increased the phosphorylation
of ATM, and the cell death induced by those compounds
was decreased by ATM/ATR inhibitor caffeine (Fig. 7a
and b). These results suggest that 3-ring compounds car-
rying terminal alkoxyl and hydroxyl groups may possess
structurally important features for DNA damage-
signaling pathway-mediated cell death that are inde-
pendent of the central pyrimidine moiety. Although it is
known that p53 is an important target of ATM and it
plays key role in DNA damage-induced cell death
[45–47], compounds C1 and C2 induced cell death in
a p53-independent manner. There are several strat-
egies that cells seem to employ to trigger p53-
independent DNA damage-induced apoptosis [46, 47].
For example, a p53 homolog p73 is implicated in it.
Upon DNA damage, ATM/ATR increases the levels of
p73 protein through the activation of transcriptional
factor E2F1 [48]. As well as p53, p73 can induce
apoptosis through death receptor pathway and mito-
chondrial apoptotic pathway [49, 50]. Furthermore,
homeodomain-interacting protein kinase 2, a serine/
threonine protein kinase, also can trigger p53-
indepdent DNA damage-induced apoptosis [47, 51].
Therefore, it will be necessary to determine the involve-
ment of those proteins in the compounds-induced cell
death in future study.
Side effects are considerable for most anticancer drugs.
Although C1 has potential to have a broad cytotoxic ef-
fect against NSCLC cells, it also showed strong cytotox-
icity against WI-38 cells. Specifically, treatment with C1
and C3 caused G2/M arrest in WI-38 cells (Fig. 8b), po-
tentially reflecting similar cell death mechanisms follow-
ing G2/M arrest as those seen in NSCLC cells. However,
derivatives of C1 with 4- or 5-carbon alkyl chain lengths
showed more moderate cytotoxic effects against WI-38
cells while retaining dramatic cytotoxicity against
NSCLC cells, suggesting that the modulation of alkyl
chain length might improve the cancer-specific cytotox-
icity of these mesogenic compounds. This may be due to
the differences in cell membrane compositions and cell
membrane permeability between cancer and normal
a b
c d
Fig. 7 Involvement of DNA damage-signaling pathway and p53 in compounds-induced cell death of A549 cells. a A549 cells cultured in the
presence of 10 μM C1 for 48 h or C2 for 72 h were harvested, and intracellular phospho-ATM expression was analyzed. Representative histograms
of three different experiments are shown. The dotted line histogram indicates cells stained with Alexa Fluor® 488-conjugated secondary antibody
alone. The broken line and filled gray histograms indicate phosphor-ATM expression in cells treated with vehicle and compound, respectively. As
a positive control, A549 cells were irradiated with 10 Gy X-ray and harvested 30 min after irradiation. b A549 cells preincubated with the caffeine
(2 mM) were cultured in the presence of 10 μM C1 or C2 for 72 h. The cells were harvested, and annexin V/propidium iodide staining was
performed. Percentages of annexin V(+) cells are presented as the mean ± SE of three independent experiments; * and ** indicate p < 0.05 and
p < 0.01. c–d A549 cells treated with p53-targeting siRNA were cultured in the presence of 10 μM C1 for 48 h or C2 for 72 h. The cells were harvested,
and then western blotting (c) and cell death analysis (d) were performed. Representative results of two different experiments are shown
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cells [52, 53]. On the other hand, compounds C2, C4,
and C5 showed no significant growth-suppressive effects
against the normal human fibroblast WI-38, which is
promising for cancer-specific agents. The response to
DNA damage varies depending on the cell type, and it is
mentioned that fibroblasts are relatively resistant to
DNA damage-induced apoptosis [45, 54]. That is why
cytotoxic effect by C2 through DNA damage-signaling
pathway might not be effective in human fibroblast WI-
38 cells. To further clarify cancer-specific cytotoxic
effects of these compounds, the cytotoxicity against
other cell types such as hematopoietic cells should be
examined in future study.
Conclusions
In conclusion, this study demonstrated that not only the
3-ring structure with terminal alkyl and hydroxyl groups
but also the alkyl chain lengths are structurally important
for the cytotoxic effects of mesogenic compounds against
human NSCLC cells. In addition, we showed that cell
cycle arrest depended on the position of the pyrimidine,
and that the cytotoxic effects in human lung-derived
normal fibroblasts varied depending on not only the pos-
ition of pyrimidine but also the terminal alkyl chain
length. Although we need to verify whether the cytotoxic
effects of these mesogenic compounds obtained in vitro
study are effective in vivo, we believe that these structure–
activity relationships will be helpful in the development of
more effective and cancer-specific agents.
Additional files
Additional file 1: Figure S1. Dose response effects of test compounds
on the growth of A549 cells. A549 cells cultured in the presence of
compounds C1 and C2 at 0.75–12 μM for 3 days were harvested, and
viable cells were counted using trypan blue exclusion assays. Data are
presented as the mean ± SE of 3 independent experiments. (DOCX 60 kb)
Additional file 2: Figure S2. Effects of test compounds on cell cycle
progression. Non-small cell lung cancer cells cultured in the presence of
test compounds (C3–C5) at 10 μM for 24–48 h were harvested, and then
cell cycle profiles were analyzed. Representative histograms are shown.
(DOCX 195 kb)
Additional file 3: Figure S3. Nuclear morphology of A549 cells treated
with C1. A549 cells (4.0 × 104 cells) were grown on chamber slides II
(IWAKI) overnight to allow adherence to the slides. After treatment with




Fig. 8 Effects of the compounds on the growth of WI-38 cells. a WI-38 cells cultured in the presence of test compounds at 10 μM for 3 days were
harvested, and viable cells were counted using trypan blue exclusion assays. Data are presented as the mean ± SE of four independent experiments.
b WI-38 cells cultured in the presence of test compounds (C1, C2, and C3) at 10 μM for 12 h were harvested, and then cell cycle profiles were analyzed.
c Cytotoxic effects of compound C1 and its derivatives with varying alkyl chain lengths are shown. WI-38 cells cultured in the presence of test
compounds at 10 μM for 3 days were harvested, and viable cells were counted using trypan blue exclusion assays. Data are presented as the
mean ± SE of four independent experiments
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30 min at room temperature. Fixed cells were washed with PBS(−),
permeabilized in 0.5 % TritonX-100 for 5 min at 4 °C, and washed with
PBS(−). The slides were stained and mounted with VECTASHIELD®
Mounting Medium with DAPI (Vector Laboratories, Inc., Burlingame, CA,
USA). Photographs of the cells were taken with an Olympus IX71 (Tokyo,
Japan) and DP2-BSW software (Olympus). Representative results are
shown. Arrow indicates mitotic cells. (DOCX 728 kb)
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